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SUMMARY 
The dissertation entitled "Development of analytical methods for the 
determination of haloperidol in commercial dosage forms" is comprised of 
two chapters. The first chapter describes a general introduction of the subject 
matter. The very relevant matter includes: 
• A brief discussion on the development and uses of haloperidol. 
• The discussion on possible degradation products under a variety of 
conditions. 
• The description of stability testing of dosage forms which provides 
evidence on how the quantity of drug substance or drug product varies 
under the influence of a variety of environmental factors such as humidity, 
temperature and light. 
• Discussion of excipients which are major fraction of the solid dosage 
forms. The characterization of individual drug/excipient interaction is an 
important part for understanding the overall behaviour of the dosage 
forms. 
• A brief discussion related to the comparison of various analytical 
techniques employed to assay active pharmaceutical ingredients in 
commercial dosage forms. 
• A well composed list of references taken from the world's leading 
scientific journals in the field is given at the end of the chapter. 
The second chapter describes a validated and sensitive spectrophotometric 
method for the determination of haloperidol in commercial dosage forms. The 
method is based on the condensation reaction of 2,4-dinitrophenylhydrazine 
with >C=0 group of haloperidol to form a coloured product which absorbs 
maximally at 456 nm. Under the optimized experimental conditions, Beer's 
law is obeyed in the concentration range of 3.6-10.8|ig/mL with linear 
regression equation of A = -0.097+0.084C and correlation coefficient, R^  = 
0.9998. The molar absorptivity was tound to be 2.84^ lO^L mol 'cm '. The 
limits of detection and quantitation of the proposed method are 0.28 and 0.89 
lig/mL, respectively. The intraday and interday precision and accuracy of the 
proposed method are acceptable with low values of RSD. The recovery results 
obtained by the proposed method vary in the range of 99.59% - 99.97%. The 
IV 
results of the proposed method are compared with those obtained by a 
reference method which indicated excellent agreement with acceptable true 
bias of both the dosage forms within ± 2.0%. 
CHAPTER! 
GENERAL INTRODUCTION 
Haloperidol was developed in the late 1950s for use in the field of anaesthesia 
and was initially used to prevent surgical shock. Research subsequently 
demonstrated its beneficial effect on hallucinations, delusions, aggressiveness, 
impulsiveness and states of excitement [1-3]. These findings led to the 
introduction of haloperidol as an antipsychotic. Hailed as a breakthrough, it 
was considered to be the most potent antipsychotic known, effective for a 
wide range of psychotic disorders, and in addition, appeared to keep side 
effects to a minimum. Since its introduction, clinical experience has suggested 
that haloperidol is indeed an effective antipsychotic, particularly beneficial for 
those who are experiencing acute hallucinations and delusions. Haloperidol's 
efficacy as an antipsychotic seems to vary. Some research suggests factors 
such as drug dose, administration of antiparkinson medication, recipient age, 
sex, and individual physiology may all change efficacies [3]. More recently 
there has been increasing concern and debate surrounding the long-term use of 
haloperidol and the subsequent development of serious adverse side effects. 
Despite these recent concerns, research in general has consistently found 
haloperidol to be an effective, well tolerated antipsychotic that produces 
minimal side effects. Consequently, in accordance with their commendations 
of drug regulatory authorities, such as the Food and Drug Administration of 
the United States of America, haloperidol is increasingly used as a comparator 
drug in clinical trials [2-4]. To an even greater extent than chlorpromazine, 
haloperidol remains the benchmark by which all other antipsychotics are 
measured. Under different abnormal conditions such as temperature, pH, light, 
and air exposure, haloperidol degrades forming several degradation products 
that have undesirable side effects. The oxidation of haloperidol could result in 
the formation of cis-4-[4-(4-chlorophenyl)-4-hydroxy-l-piperidinyl]-l-(4-
fluoro-phenyl)-l-butanone N-oxide and trans-4-[4-(4-chlorophenyl)- 4-
hydroxy-l-piperidinyl]-l-(4-fluorophenyl)-l-butanone N-oxide while its 
hydrolysis in acidic and basic medium could form 4- [4-(4-chlorophenyl)-3,6-
dihydro-l(2H)-piperidinyl]-l-(4-fluorophenyl)-l- butanone and 4-[4-(4-
chlorophenyl)-4-hydroxy-l -piperidinyl]-1 -(4-hydroxyphenyl)-1 -butanone, 
respectively [5-10].The chemical structures of haloperidol and its degradation 
products are shown in Schemel.l. 
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Pharmaceutical stability may be defined as the capability of a particular 
formulation, in a specific container/ closure system, to remain within its 
physical, chemical, microbiological, therapeutic, and toxicological 
specifications, during transport, storage and use. Chemical degradation may 
result in a loss of potency or an increase in drugs toxicity, so that clinical use 
of a medicine must be unacceptable if the degradation is relatively great [11]. 
When a drug dosage form is altered (by dissolution, pulverization, or addition 
to other materials) or the environment of the drug is modified by changes in 
storage condifions, the stability of a drug may be affected [12-17]. Although 
there are exceptions, 90% of labeled potency generally is recognized as the 
minimum acceptable potency level. 
Stability testing forms an important part of the process of drug development; it 
provides evidence on how the quality of drug substance or drug product varies 
with time under the influence of a variety of environmental factors, such as 
humidity, temperature, and light. The stability studies of drugs can be 
performed at the original product ("real-time" tests or long-term tests at 
specific temperatures and relative humidity representing storage conditions 
experienced in the distribution chain of the climatic zones of the country or 
region of the world concerned; accelerated stability tests; pharmacies storage 
tests) or at remainder doses of these products. The chemical stability is 
evaluated by testing quantity of drug at different time during the storage. The 
aim of the stability studies is to determine the shelf life of the product and its 
optimum storage conditions [15-17]. The drugs which are marketed may have 
different dosage forms. Formulation can be categorized according to the route 
of administrafion [10]. 
The properties of the drug substance can have a significant effect on the 
physical and chemical behaviour the drug product. A review of the drug 
substance concerning physical and chemical properties is performed in 
relation to the excipients characteristics. For example, particle shape of the 
drug substance can impact the bulk properties of a drug product powder and 
can influence flow properties of the drug/excipient blend in the manufacturing 
process [18]. The ultimate influence of the drug substance particle 
characteristics on drug product performance will depend, in part, on the 
characteristics of the excipients. 
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Excipients 
Excipients typically are the major fraction of the solid dosage form. As such, 
the characterization of the individual drug/excipient interaction is an important 
part of understanding the overall behaviour of the dosage form. It is well 
known from studies of drug substances that water associated with the drug 
substance can influence chemical degradation rates, dissolution, powder flow, 
and other physical properties [19]. Likewise, the physical state of the excipient 
can impact the performance of the drug product. The regulatory status of the 
excipient is an additional consideration. In the United States, an excipient that 
is "generally recognized as safe," (GRAS) for it's intended use can be 
exempted from premarket approval requirements of the Federal Food, Drug, 
and Cosmetic Act [20]. In Europe non compendial excipients must meet food 
additive requirements. Are the excipients well characterized with regard to 
safety? If the excipients are not GRAS or do not have food additive status, 
have the excipients been used in approved products in the United States or 
Europe? Is the use of this excipient in pharmaceutical products documented in 
the literature? In the absence of such information, the safety profile of the 
excipient must be demonstrated, thereby adding an additional regulatory 
burden [21]. The source of excipients used in the drug product should be 
considered. A general compendia guidance, such as the United States 
Pharmacopeia (USP), recommends that suppliers of excipients meet current 
good manufacturing practices (cGMP) requirements. 
Solid Dosage Forms 
Solid-state reactions in the dosage form can occur when the drug substance 
intrinsically is reactive and may be accelerated by interaction with excipients 
(chemical/physical interaction) or induced by excipients (where the excipient 
does not chemically interact but promotes the degradation of the drug 
substance) [22]. Some incompatibilities of drug substance functional groups 
and excipients are documented in the literature and can provide guidance in 
the design phase of compatibility studies. For example, primary and secondary 
amines can react with reducing agents (e.g., lactose, glucose, and maltose) to 
form glycosylamines [23-25]. An alternative to reducing sugars is the use of 
non-reducing carbohydrates such as mannitol and sucrose. The due diUgence 
analysis should include a review of the fundamental chemistry of the drug 
substance and the excipients. Two common techniques to examine drug/ 
excipient compatibility are differential scanning calorimetry (DSC) and 
chromatographic analysis [26-27]. Differential scanning calorimetry detects 
interactions that are accompanied by a change in heat. These interactions 
include chemical degradation, melting and mixing. Chromatographic analysis 
of drug/excipient mixes placed under accelerated storage is a complementary 
technique that determines the potential formation of degradation species over 
time. As a first approach to drug/excipient compatibility the use of DSC is 
evident throughout the literature [28-30]. The advantages of DSC trials 
include the small amounts of material necessary for the study and the facile 
nature of the technique. In addition to DSC, thermo gravimetric analysis 
(TGA) offers a complementary view of potential incompatibilities. Small 
weight changes due to chemical reactions can readily distinguish from thermal 
changes that occur without weight changes (melting, crystallization, or 
polymorphic changes) [19]. Traditionally, 50/50 (w/w) mixtures of the drug 
and the excipient are tested. Ranges of drug/excipient ratios also should be 
tested, since interactions may be concentration dependent [31]. More recent 
studies that use high-sensitivity DSC [32] and isothermal microcalorimetry 
[33] suggest that the intentional incorporation of water into the sample may 
provide information regarding the moisture sensitivity of the product. After 
initial binary studies are performed, similar studies can be performed on 
tertiary or higher order mixtures, although the interpretation of such data can 
be difficuh due to the potential complexity of the interactions. 
Other techniques such as fourier transform infrared (FTIR) 
spectroscopy, x-ray powder diffraction, and liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) analysis have also been used to investigate 
drug/excipient compatibility [34]. For example, infrared (IR) studies of 
amoxicillin trihydrate in ethyl cellulose granules suggested hydrogen bonding 
between the excipient and the active ingredient [35]. The application of 
complementary techniques is useful in determining the extent and nature of 
interactions between the drug substance and the excipients. Compounds in 
early preclinical development will have limited stability data. Compatibility 
information provides a means to predict the potential challenges that may be 
faced as clinical development proceeds. 
Analysis of compatibility studies requires careful interpretation of the data as 
demonstrated in studies of polyvinylpyrrolidone (PVP) with a pharmaceutical 
drug substance [36]. In this example, exposure of the drug product to an 
elevated temperature and humidity (40 C/75% relative humidity) resulted in 
the physical change of the excipient from the glassy to the rubbery state (the 
glass transition state change is noted by a change in the specific heat capacity 
of the material) [37], resulting in a loss of pore structure of the solid mix and a 
concomitant decrease in the dissolution rate. This effect is not seen in long-
term studies at 30 C/60% RH (below the glass transition temperature for 
PVP). Thus, the results of thermal methods or elevated temperature and 
humidity studies to explore compatibility may not be predictive, necessarily, 
of the long-term behaviour of the dosage form but can provide, ultimately, a 
useful data set in understanding the nature of the drug/excipient interaction. 
Table!.1. summarizes the utility of some of the analytical techniques used to 
characterize drug/excipient compatibility. 
Subsequent to compatibility studies, prototype formulations can be made and 
tested for physical and chemical performance. Consistent with the ultimate 
regulatory requirements of solid dosage forms [38], multiple aspects of 
performance are examined including dissolution, disintegration, hardness, 
friability, assay, and purity profile [39]. 
Table 1.1. Drug substance/excipient compatibility testing-techniques 
and the utility of the information derived. 
Investigative 
technique 
Measurement Utility of data 
DSC 
TGA 
Chromatographic 
Analysis 
Microcalorimetry 
X-ray diffraction 
Microscopy 
LC-MS/MS 
Energy is absorbed or 
released by a sample as it is 
heated, cooled, or held at a 
constant temperature 
Weight changes by a 
sample as it is heated, 
cooled, or held at a constant 
temperature 
Chemical interactions of 
the sample with the 
stationary phase and the 
mobile phase 
Absorption or release of 
heat from solution sample 
Scattering of x-ray 
radiation by a solid sample 
Magnified appearance of 
sample 
Chromatographic 
separation and 
fragmentation of molecular 
species 
Physicochemical 
compatibility of drug and 
excipients 
Physicochemical 
compatibility of drug and 
excipients 
Excipients, drug product 
purity; excipient-drug 
substance chemical 
compatibility 
Physicochemical 
compatibility of drug and 
excipients; solution 
applications 
Polymorph 
characterization 
Particle size morphology 
Impurity, 
degradation product 
identification 
Analytical Techniques 
In the field of pharmaceutical research, the analytical investigation of bulk 
drug materials, intermediates, drug products, impurities, drug formulation 
degradation products, and biological samples containing the drugs and their 
metabolites is very important. From the commencement of official 
phannaceutical analysis, analytical assay methods were included in the 
compendial monographs with the aim to characterize the quality of bulk drug 
materials by setting limits of their active ingredients content [40-41]. In recent 
years, the assay methods on the monographs include titrimetry, spectrometry, 
chromatography, and capillary electrophoresis; also the electro-analytical 
methods can be seen in the literature. The present state-of-the art is replicated 
through the data in the given Table 1,2. based on the edition of European and 
US Pharmacopoeias [42-45]. 
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Table.1.2. Proportion of various analytical methods prescribed for the 
assay of bulk drug materials in Ph. Eur. 4 and USP XXVIl. 
Method Ph.Eur. 4(%) USP 27(%) 
HPLC 
GC 
Titration 
Acid- base 
Aqueous mixtures 
Indicator 
Potentiometric 
Non-aqueous 
Indicator 
Potentiometric 
Redox 
Other (complexometry, 
argentometry, etc.) 
UV-vis spectrophotometry 
Microbiological assay 
(antibiotics) 
Other (IR, NMR, Polarimetry, 
fluorimetry, 
Atomic absorption 
spectroscopy, polarography, 
gravimetry etc.) 
15.5 
2.0 
69.5 
57.5 
21.0 
6.5 
14.5 
36.5 
9.5 
27.0 
6.5 
5.5 
9.5 
3.0 
44 
2.5 
40.5 
29.5 
5.5 
4.5 
1.0 
24 
14 
10 
5.5 
5.5 
8.5 
2.5 
0.5 2.0 
Ph.Eu.4 = The European Pharmacopoeia,4"' edition (2002) 
USP 27 = United States Pharmacopoeia xxvii (2004) 
11 
Titrimetric methods 
The literature search reveals that there are few recent methods that employ this 
technique for analysis of pharmaceuticals. There are many advantages 
associated with titrimetric methods which include saving time and labour, high 
precision and the fact that there is no need of using reference standards. In the 
past titrimetric methods have been used for the determination of captopril [46] 
and albendazole in commercial dosage forms [47]. Rajendra-prasad and 
coworkers [48] have developed two titrimetric methods for the determination 
of hydroxyzine dihydrochloride in pure form and in tablet. The methods were 
based on acid-base reactions in which the hydrochloride content of the drug 
was determined by titrating with an aqueous standardized NaOH solution 
either visually using phenolphthalein as indicator or potentiometrically using 
glass-calomel electrode system. The procedures were also applied for the 
determination of hydroxyzine dihydrochloride in its dosage forms. The results 
were found to be in good agreement with those obtained by the reference 
method. A titrimetric method was also reported [49] for the determination of 
doxycycline hyclate in bulk drug and its commercial dosage forms. In this 
method, doxycyline hyclate was treated with a known excess of bromate-
bromide mixture in acidic medium and the residual bromine is back titrated 
iodometrically. British Pharmacopoeia [50] recommended potentiometric 
titration for assay of raw materials. De Sousa and Cavalheiro [51] have 
developed a titrimetric procedure for the determination of minoxidil using 
KMn04 as oxidizing agent. 
12 
Spectrophotometry 
Another important group of methods which find an important place in 
pharmacopoeias are spectrophotometric methods based on natural UV 
absorption and chemical reactions [52].The advantages of these methods are 
low time and labour consumption. The precision of these methods is also 
excellent. The use of UV-Vis spectrophotometry especially applied in the 
analysis of pharmaceutical dosage form has increased rapidly over the last few 
years [53-56]. The colorimetric methods are usually based on the following 
aspects: 
1. Complex-formation reaction. 
2. Oxidation-reduction process. 
3. A catalytic effect. 
It is important to mention that colorimetric methods are regularly used for the 
assay of bulk materials. For example, the blue tetrazolium assay is used for the 
determination of corticosteroid drug formulations. The colorimetric method is 
also exploited for the determination of cardiac glycosides and is presented in 
European Pharmacopoeia. Several approaches using spectrophotometry for 
determination of antipsychotic drugs in bulk and formulations have been 
reported and details of these methods are recorded in (Tablel.3). 
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Table 1.3. Quantitative analysis of antipsychotic drugs in 
pharmaceutical formulations by spectrophotometry. 
Name of drug 
Quetiapine 
fumarate 
Olanzapine 
Thioridazine 
hydrochloride 
Aripiprazole 
Haloperidol 
Tiapride 
Chlorpromazine 
hydrochloride 
Promethazine 
hydrochloride 
Phenothiazine 
Reagents used 
Tropaeolin 000 
Potassium iodate and 
Leucocrystal violet 
Chloroamine T and 
Rhodamine B 
N-
Bromosuccinimide, 
metol,isonicotinic 
acid hydrazide. 
N-Bromosuccinimide 
and 
amaranth 
N-Bromosuccinimide 
and Methylene blue 
2,3-Dichloro-5,6-
dicyano-p-
benzoquinone 
Bromocresol green 
Eriochrome black T 
p-Chloranilic acid 
N-Chlorosuccinimide 
N-Chlorosuccinimide 
N-Chlorosuccinimide 
(Xmax) 
480 
598 
458 
610 
520 
660 
457 
413 
510 
520 
534.5 
517 
516.5 
Concentration 
range 
(^g/ml) 
2.0-20 
0.05-2.0 
0.1-2.0 
0.4-8.0 
0.8-4.8 
0.8-5.6 
10-120 
2-24 
2-9 
10-100 
4-40 
2-32 
2-28 
References 
[57] 
[58] 
[58] 
[59] 
[60] 
[60] 
[61] 
[61] 
[62] 
[63] 
[64] 
[64] 
[64] 
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Amisulpride 
Amisulpride 
Ziprasidone 
Buclizine 
Paliperidone 
Palmitate 
Paliperidone 
Palmitate 
Trimipramine 
Nitrous acid, 
sulphamic acid and 
ethylacetoacetate 
Nitrous 
acid,sulphamic acid 
and 1-benzoylacetone 
Nitrous 
acid,sulphamic acid 
and8-
hydroxyquinoline 
Alizarin Red S 
Alizarin Red S 
Wool Fast Blue 
2,3-Dichloro-5,6-
dicyano-1,4-
benzoqunone 
7,7,8,8-Tetra 
cyanoquinodimethane 
438 
446 
545 
420 
420 
590 
385 
839 
1-24 
1-24 
1-20 
2.5-15 
2.5-15 
0-200 
0-200 
2.0-32 
1651 
|65] 
165] 
[66] 
166] 
[67] 
[67] 
[681 
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The field of kinetic methods of analysis has been developing since the late 
1950s. Although the field is now mature, it has recently been undergoing a 
major resurgence in activity. The renewed interest can be attributed to 
advances that have been made in principles, in automated instrumentation, in 
understanding chemical and instrumental system, in data treatment methods, 
and in analytical application. Also, it is becoming clear that the kinetic 
approach to analytical chemistry is rather general with several advantages over 
traditional equilibrium approach [69-71]. Essentially, kinetic methods rely on 
the measurements of concentration changes (detected via signal change) in a 
reactant (which may be the analyte itself) with time after the sample and 
reagents have been mixed manually or automatically. There are several 
approaches that can be used for the determination of single components in the 
absence of any kinetic interference (Table 1.4). However, fixed-time and 
initial-rate methods have been used more frequently for the determination of 
drugs in pharmaceutical formulations and biological fluids [72-74]. The use of 
catalysts to accelerate analytical reaction is feasible with both reaction rate and 
equilibrium determination. In this concern, the use of micellar media in kinetic 
method is recently encouraged to enhance the rate of reaction (through 
micellar catalysis) and additionally improve the sensitivity and selectivity 
which in turn reduce the analysis time for the anaylte [75-77]. 
Muhicomponent kinetic determinations, often called as differential rate 
methods, are also receiving popularity in the field of pharmaceutical research. 
Two new approaches i.e., kinetic wavelength pair method [78] and H-point 
standard addition method [79] have been proposed for dealing with 
overlapping spectra of components in the binary mixtures. 
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Table 1.4. Kinetic approaches for the determination of single 
component. 
A. Direct-computation B. Curve-fitting methods 
1. Integral methods 
a. Fixed time 
i. One-point 
ii. Two-point 
iii. Multipoint 
b. Variable-time 
i. One-point 
ii. Two-point 
2. Rate methods 
Initial-rate 
3. Intermediate-rate 
Integrated-signal methods 
1 .Integral methods 
a. Linear responses 
b. Non-Linear response 
i. Direct computation 
ii. Predictive (extrapolation) 
2.Rate methods 
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Multicomponent kinetic determinations, often called as differential rate 
methods, are also receiving popularity in the field of pharmaceutical research. 
Two new approaches i.e., kinetic wavelength pair method [78] and H-point 
standard addition method [79] have been proposed for dealing with 
overlapping spectra of components in the binary mixtures. 
A Kinetic spectrophotometric method for determination of ramipril was 
developed based on the reaction of carboxylic acid group of the drug with a 
mixture of potassium iodate and potassium iodide in aqueous medium at room 
temperature [80].The reaction was followed spectrophotometrically by 
measuring the increase in absorbance at 352 nm as a function of time. The 
initial-rate and fixed-time methods were adopted for construction of 
calibration curves. Ranitidine was determined by a kinetic spectrophotometric 
method based on its catalytic effect on the reaction between sodium azide and 
iodine [81]. Ashour and Khateeb [82] have developed a simple kinetic 
spectrophotometric method for the determination of pravastatin based on its 
reaction with 4-chloro-7-nitrobenzo-2-oxa-l,3-diazole in acetone medium 
.The absorbance at 462 nm increases with the time and hence, intial-rate and 
fixed-time methods were adopted for determination in commercial dosage 
forms. Rahman and Coworkers [83,84] have described kinetic 
spectrophotometric methods for the determination of lansoprazol using initial-
rate and fixed time procedures. The literature survey revealed that some 
kinetic spectrophotometric methods have been developed using potassium 
permaganate as oxidant [85-89]. Table 1.5 shows the reagents used for the 
development of kinetic spectrophotometric methods for the assay of drugs in 
pharmaceutical formulations [82-89]. 
18 
Table 1.5. Kinetic spectrophotometric methods for the determination 
of pharmaceuticals 
Pharmaceuticals 
Ramipril 
Ranitidine 
Pravastatin 
Lansoprazole 
Alftizosin 
Norfloxacin 
Tetracycline 
Hydrochloride 
Gemifloxacin 
Cephalosporins 
Reagents 
KIO3 and 
KI 
Sodium 
azide and I2 
4-Chloro-7-
nitrobenzo-
2-oxa-l,3-
diazole 
Fe(III) 
Zn(II) 
KMn04 
KMn04 
KMn04 
KMn04 
KMn04 
Cerium (IV) 
sulphate 
Potassium 
iodate 
And 
potassium 
iodide 
(>-max) 
352 
348 
462 
445 
510 
610 
530 
610 
603 
610 
411 
352 
Kinetic 
method 
adopted 
Initial 
rate 
Fixed 
time 
Fixed 
time 
Initial 
rate 
Fixed 
time 
Initial 
rate 
Fixed 
time 
Fixed 
time 
Fixed 
time 
Fixed 
time 
Intial 
rate 
Fixed 
time 
Fixed 
time 
Initial 
rate 
Fixed 
time 
Linear 
Range 
(jig/mL) 
10-7 
4-24 
15-50 
10-70 
0-200 
120-300 
5-150 
5-150 
2-30 
2-20 
1-30 
2-9 
10-50 
10-50 
References 
[80] 
[81] 
[82] 
[83] 
[84] 
[85] 
[86] 
[87] 
[88] 
[89] 
[89] 
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High Performance Liquid chromatography 
High performance liquid chromatograpiiy (HPLC) is the most popular 
instrumental technique used for the analysis of pharmaceuticals. It was in the 
year 1980, HPLC methods appeared for the first time for the assay of bulk 
drug materials [90]. As can be seen in Table 1.2 this has become the principal 
method in United States Pharmacopoeia [91] and to a lesser extent but one of 
the most widely used methods also in the European Pharmacopoeia [41]. The 
specificity of the HPLC method is excellent and simultaneously sufficient 
precision is also attainable. However, it has to be stated that the astonishing 
specificity, precision and accuracy are attainable only if wide-ranging system 
suitability tests are carried out before the HPLC analysis. For this reason the 
expense to be paid for high specificity, precision and accuracy is also high. In 
liquid chromatography the choice of detection approach is critical to guarantee 
that all the components are detected. One of the widely used detectors in 
HPLC is UV detector which is capable of monitoring several wavelengths 
concurrently; this is possible only by applying a multiple wavelength scanning 
program. If present in adequate quantity, UV detector assures all the UV-
absorbing components are detected. Monser and Trabelsi [9] have developed 
HPLC method for simultaneous determination of haloperidol and its 
degradation products such as cis-4-[4-(4-chlorophenyl)-4-hydroxy-l-
piperidinyl]-1 -(4-fluorophenyl)-1 -butanone N-oxide, 4-[4-(4-chlorophenyl)-4-
hydroxy-1 -piperidinyl]-1 -(4-hydroxyphenyl)-1 -butanone,4-[4-(4-
chlorophenyl)-3,6-dihydro-1 (2H)-piperidinyl]-1 -(4-fluorophenyl)-1 -butanone 
and trans-4-[4-(4-chlorophenyl)-4-hydroxy-1 -piperidinyl]-1 -(4-fluorophenyl)-
1-butanone N-oxide in pharmaceutical formulations. In this technique, a 
porous graphite carbon column was used and separation was achieved in an 
isocratic elution mode using tetrahydrofuran/water (55:45%) containing 0.5% 
trichloroacetatic acid as mobile phase. The quantification of haloperidol in 
human serum was done after extraction with diethyl ether-n-heptane (50:50%). 
Chandraiah and Reddy [92] have developed HPLC method with UV detection 
at 285nm and subsequent validation for the content uniformity determination 
of haloperidol in marketed tablet samples. The method uses isocratic mobile 
phase of 0.1 M sodium phosphate buffer (pH adjusted to 6.5 with sodium 
20 
hydroxide solution) and acetonitrile (65:35v/v) on reverse phase Lichrosphere 
RP-lOO C8 column. A specific HPLC method was also described for the assay 
of haloperidol, together with an adequate separation of its degradation 
products [93].The method is based on the use of an octadecylsilane stationary 
phase column under isocratic conditions. The mobile phase consisted of 
50mM sodium phosphate monobasic pH 2.5-acetonitrile-THF-l EA 
(63:34:3:0:1;V/V/V/V) adjusted with o-phosphoric acid to a pH of 2.5.The 
degradation was performed in hydrochloric acid, sodium hydroxide and 
hydrogen peroxide. The main degradation product was identified. The 
linearity was found to be in the range of 10-50|j.g/mL with correlation 
coefficient of 0.9995. Ebrahimzadeh and coworkers [94] have developed a 
simple quantitative method for pre-concentration and determination of 
haloperidol in biological samples using ultrasound-assisted emulsification 
microextraction, based on the solidification of floating organic droplet 
combined with HPLC-DAD. The extraction efficiencies were more than 90% 
and preconcentration factors were obtained between 119-122.The calibration 
curves were linear in the range of 4-1000 |ig/mL with limit of quantification of 
4-8 |ig/mL. 
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SPECTROPHOTOMETRIC METHOD 
FOR THE DETERMINATION OF 
HALOPERIDOL USING 
2,4-DINITROPHENYLHYDRAZINE 
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1. INTRODUCTION 
Haloperidol is a butyrophenone derivative with antipsychotic properties. It is 
chemically known as 4-[4-(4-chlorophenyl)-4-hydroxy-l-piperidyl]-l-(4-
flourophenyl) butane-1-one with molecular weight of 375.86g/mol. It is 
practically insoluble in water (1.4mg/100 mL) [1]. Haloperidol is a tertiary 
amine that has the ability to form interface between water / lipid at a very low 
concentration of the order of lO'^ M [2]. It behaves as a potent membrane 
permeability blockers and the therapeutic properties are due to its DT 
antagonist activity [3]. It is used in the manifestations of chronic psychosis 
including Schizophrenia and manic states [4]. It is also used for the treatment 
of severe behaviour problems in children with symptoms' of impulsivity. 
difficulty in sustaining attention, mood liability and poor frustration tolerance 
[5,6]. Haloperidol is readily absorbed after oral administration and is localized 
in tissues. It is extensively metabolized in the liver and only 1% of the 
administered dose is excreted unchanged in the urine [7]. The elimination half 
-life of haloperidol is 17 to 18 hours [8] and hence exerts prolonged effects. In 
addition, haloperidol is unstable when exposed to elevated temperature and 
light [9, 10]. 
Haloperidol is available in various dosage forms including immediate release 
oral and intramuscular preparations as well as a sustained release 
intramuscular product. These pharmaceutical preparations contain excipients 
that can impede the determination of haloperidol .Therefore; it is required to 
search new spectrophotometric methods that can be used to determine 
haloperidol in pharmaceutical dosage forms. Many methods have been 
reported for the determination of haloperidol in commercial dosage forms. 
Spectrophotometric methods are frequently employed as the instrumentation is 
less expensive and easily available in all research and quality control 
laboratories. In pharmaceutical analysis, derivative spectrophotometry has 
been employed to determine haloperidol in presence of excipients 
[11-13]. The simultaneous spectrophotometric method is also reported for the 
determination of haloperidol and trihexyphenidyl in tablet formulations [14]. 
The assay was also carried out using molecular interaction between 
haloperidol and n - acceptors such as chloranilic acid, 7,7,8,8-
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tetracyanoquinodimethane, 2,3-dichloro-5, 6-dicynano-1, 4-benzoquinone, 
tetracyanoethylene, 2,4,7-trinitro-9-fluorenon and 2,3,5,6-tetrabromo-l,4-
benzoquinone[ 15,16]. Extractive spectrophotometric and spectroflurometric 
methods were also reported based on the formation of chloroform extractable 
ion-pair complexes with eriochrome black T at pH 1.85 [17] and alizarin red S 
at pH 3.4 [18]. In addition some other techniques such as HPLC [19], GC [20] 
and thin layer chromatography have also been reported for determination of 
haloperidol [21]. Moreover, HPTLC is used for the determination of 
haloperidol in pharmaceutical preparations [22]. 
This chapter describes a simple and sensitive spectrophotometric method for 
the determination of haloperidol in pharmaceutical preparations. The proposed 
method is based on the reaction of haloperidol with 2,4- dinitrophenyl 
hydrazine (DNPH).The method is validated as per International Conference on 
Harmonization (ICH) guidelines [ 23]. 
2. Experimental 
2.1. Chemicals and Reagents 
All chemicals and reagents were of analytical reagent grade. Haloperidol was 
purchased from Sigma Chemical Company (St.Louis, MO, USA).2,4-
Dinitrophenyl hydrazine was procured from Loba Chemie, Mumbai, India. 
Methanol and potassium hydroxide were obtained from Merck (India) and 
Thomas Baker (Mumbai, India), respectively. 
Haloperidol pharmaceutical preparations such as Serenace tablets 
(10mg/tablet;RPG Life Sciences, Ltd, Mumbai, India) and Hexidol tablets 
(lOmg/tablet; Torrent Pharmaceuticals, Ahmedabad, India) were purchased 
from the local market. 
2.2. Apparatus 
All spectral measurements were carried out using a Shimadzu UV- Visible 
spectrophotometer (Model UV-1800, Kyoto, Japan). All measurements were 
performed at 25±2°C. 
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2.3. Standard Solutions 
Haloperidol (0.012%) was prepared by dissolving the accurately weighed 
amount in ethanol and diluted to the mark with the same solvent.DNPH 
(0.05%w/v) was freshly prepared in methanol. KOH solution (10%) was 
prepared by dissolving lOg of NaOH in lOOmL methanol. 
3. Procedures 
3.1. General procedure for determination. 
Different aliquots of haloperidol solution (120|j.g/mL) corresponding to 36-
lOSfag were transferred into a series of boiling tubes. Then 2.0 mL of 0.05% 
DNPH was added followed by 0.5 mL of concentrated HCl. The contents were 
mixed and heated on a boiling water bath for 25 min. After cooling at room 
temperature, 5.0mL of 10% methanolic KOH was added and then the contents 
were transferred into a 1 OmL volumetric flask. The volume was made upto the 
mark with methanol. The absorbance of the solution was measured at 456nm 
against a reagent blank solution prepared by the same way without drug .The 
concentration of haloperidol in the unknown sample was read from the 
calibration graph or calculated using the corresponding regression equation. 
3.2. Procedure for tablet 
Ten tablets of haloperidol were accurately weighed and crushed well to a fine 
powder. A portion of the powder equivalent to 12 mg haloperidol was 
transferred into a conical flask. The haloperidol was extracted with 2x20mL of 
methanol by shaking. It was then filtered through Whatmann No. 42 filter 
paper into a 1 OOmL standard flask. The volume was completed up to the mark 
with methanol. The nominal content of haloperidol in the tablet was assayed 
either from the calibration curve or using the corresponding regression 
equation. 
3.2. Determination of Stoichiometry 
The molar combining ratio between haloperidol and DNPH was evaluated by 
Job's method of confinuous variations. In this method, solutions of haloperidol 
and DNPH with identical molar concentrations were mixed in varying volume 
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ratios (0.1+ 0.9, 0.2+0.8, 0.3+0.7— 0.9 + 0.1 mL) in such a way that the 
total volume of each mixture was the same. The absorbance measured at 
456nm was plotted against the mole fraction of drug. 
4. Results and Discussion 
Attempt has been made to design a simple and sensitive spectrophotometric 
method for quantification of haloperidol based on its derivatization with 
DNPH. DNPH has been used to detect qualitatively the presence of carbonyl 
group in a compound. In our study, haloperidol contains carbonyl group in its 
structure and hence goes under condensation reaction with DNPH to produce a 
coloured product. The absorption spectra of haloperidol, DNPH and the 
product are shown in Fig.2.1.The condensation product absorbs maximally at 
456 nm. 
Job's method of continuous variations [24] was applied to determine the 
combining ratio between haloperidol and DNPH. Job's plot (Fig.2.2) shows 
that the interaction between the drug and DNPH occurs in equimolar basis i.e., 
one mole of the drug is condensed with one mole of DNPH. The reaction 
between haloperidol and DNPH may be considered as addition -elimination 
reaction. In this study nucleophilic-addition of -NH2 group to D C=0 group 
occurs and then one water molecule is eliminated. The reaction mechanism is 
shown in Scheme 2.1 
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Fig. 2.1. Absorption spectra of (A) haloperidol (ImL; 0.012%)+ DNPH 
(2mL;0.05%) + Cone. HCl (O.SraL) + KOH (5mL;10%) diluted to 
lOmLwith methanol) against reagent blanlc (B) Reagent blank; 
DNPH (2mL; 0.05%) + Cone. HCl (O.SmL) + KOH (5mL; 10%) 
diluted to lOmL with methanol. (C) haloperidol (lmL;0.012%) 
against methanol. 
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Fig.2.2. Job's plot for estimation of combining ratio between haloperidol 
and DNPH. 
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Scheme 2.1 Condensation reaction between haloperidol and DNPH. 
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5. Optimization Of Parameters 
A series of experiments were conducted to establish the optimum conditions 
for the proposed method. In the study, one parameter was varied while 
keeping others constant and its effect on the absorbance was observed. 
5.1. Effect of Reagent Concentration 
The addition of 1.8 mL of DNPH (0.05% w/v)was found to be sufficient to get 
the maximum and reproducible absorbance values for the haloperidol 
concentration range of 3.6-10.8^g/mL (Fig.2.3) .Further increase in 
concentration of DNPH caused no change in absorbance value. Therefore, 
2.0mL of 0.05% DNPH solution was chosen as the optimum value for 
subsequent measurement. 
5.2. Effect of concentration of KOH 
The effect of the concentration of KOH was studied using various volumes of 
10%KOH and a constant concentration of haloperidol (12|ig/ml).It was found 
that maximum colour intensity was achieved with 5mL of 10% methanolic 
KOH. Further increase in concentration had no significant effect on the 
absorbance value.Therefore, 5ml of 10% methanolic KOH was chosen as an 
optimum value. 
5.3. Effect of HCI concentration 
The influence of the concentration of HCI on the formation of the 
condensation product was studied using various volumes of concentrated HCI. 
It was observed that 0.45mL was sufficient for the formation of condensation 
product Fig.2.4, Therefore, 0.5ml of Cone. HCI was used in all subsequent 
measurements. 
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Fig.2.3. Effect of DNPH concentration on the absorbance of the product 
[haloperidol (12 ^g/mL), HCI (0.5 mL), 10% KOH (5 mL)|. 
1.12-
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Fig.2.4. Effect of HCI Concentration on the absorbance of the product 
[haloperidol (12 Hg/mL), 0.05% DNPH (2 mL), 10% KOH(5niL)]. 
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5.4. Effect of temperature and heating time 
The effects of temperature and heating time on the formation of coloured 
product were also examined. At room temperature the addition of DNPH to 
haloperidol solutions did not produce any coloured product and hence higher 
temperature was required to accelerate the reaction. Maximum colour intensity 
was obtained when the reaction mixture was heated on a boiling water bath for 
23 minutes and further heating did not affect the colour intensity Fig.2.5. 
Therefore, 25 minutes heating was carried out in all absorbance 
measurements. 
a> 
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<o 
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5 
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~T~ 
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Fig.2.5. Effect of heating time on the formation of condensation product. 
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6. Method Validation 
6.1. Linearity and Range 
After optimization of reaction variables, it is important to Icnow the 
concentration limit of haloperidol at which the reaction is quantitative. The 
calibration curve was constructed by analyzing seven different concentrations 
of standard haloperidol solution. It is found that Beer's law was valid over the 
concentration range of 3.6-10.8 |ig/ml at 456nm with molar absorptivity of 
2.84x10'' Lmof' cm' .The regression analysis of calibration data using the 
method of least squares was performed to evaluate the intercept, slope, 
regression coefficient (r) and standard deviation of slope and intercept. The 
data of regression analysis are given in Table 2.1.The limits of detection 
(LOD) and quantitation (LOQ) were calculated using the equations: 
LOD = 3.3Sa/b,and 
LOQ=10Sa/b 
Where Sa is the standard deviation of intercept, b is the slope of calibration 
graph. The high value of molar absorptivity and low value of LOD indicated 
the high sensitivity of the proposed method. The correlation coefficient 
(0.9998) also suggested the good linearity of the calibration graph. 
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Table 2.1. Optical characteristics and statistical data of the regression 
equation of the proposed method. 
Parameters Observed value 
Colour 
Absorption maximum (Xmax) 
Beer's Law limits (^g/mL) 
Molar absorptivity (liter mole' cm") 
Coefficient of correlation (r ) 
Intercept (a) 
Slope (b) 
Limit of detection (ftg/ml) 
Limit of quantification (|iig/ml) 
Standard deviation of intercept (Sa) 
Standard deviation of slope (Sb) 
Red 
456nm 
3.6-10.8 
2.84x10^ 
0.9998 
-0.097 
0.084 
0.28 
0.83 
0.002 
2.81x10 ,-4 
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6.2 Precision and Accuracy 
Precision of the proposed method was investigated by analysing the 
haloperidol at three different concentration levels: 4.8, 7.2 and 10.8 |ig/mL. 
The intra-day precision was assessed by analysing in five replicates during the 
same day and inter-day precision was carried out in five replicates for 5 
consecutive days. The results are summarized in Table 2.2. Low relative 
standard deviation (<1.0%) values for intra-day and inter-day analysis 
indicated good precision of the proposed method. The percent relative error 
was also found to be smaller than ± 0.5% which showed high accuracy of 
the method. 
6.3 Selectivity 
The selectivity of the proposed method was evaluated by monitoring the 
haloperidol standard solution in presence of tablet excipients such as lactose, 
sucrose, magnesium stearate, starch, gelatine, talc, colloidal silicon dioxide, 
microcrystalline cellulose and sodium lauryl sulphate. It was found that the 
excipients did not interfere in the determination of haloperidol. Comparison 
with existing metliods 
The performance of the proposed method is compared with the exisfing 
methods using different analytical techniques (Table 2.3). As can be seen 
from the table that the proposed method is more sensitive among the 
spectrophotometric methods with low RSD value. However, the proposed 
method requires heating of the reaction mixture for about 25 min. The 
performance of the proposed method is also comparable with other methods 
involving sophisticated instrumentation. The RSD values are much higher for 
'^ F NMR, GC and HPTLC methods. 
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Table 2.2. Accuracy and precision of the proposed method for analysis of 
haloperidol. 
Haloperidol (^g/mL) 
Taken 
4.8 
7.2 
10.8 
4.8 
7.2 
10.8 
Found ^i SD 
4.84±0.08 
7.22±0.01 
10.85±0.02 
Inter 
4.80±0.013 
7.21±0.02 
10.84±0.02 
Intra 
RSD" 
0.51 
0.49 
0.72 
-day accuracy and precision 
(%) Error 
0.76 
0.2 
0.62 
X%) SAE*" 
0.011 
0.016 
0.035 
•-day accuracy and precision 
0.29 
0.02 
0.18 
0.06 
0.14 
0.42 
0.006 
0.007 
0.009 
Ci.^  
0.634 
0.611 
0.896 
0.358 
0.020 
0.227 
a: (mean of five determinations) 
b: (RSD : Relative standard deviations) 
c: (RE: Relative error) 
d: (SAE = standard analytical error) 
e: (CL = Confidence limit at 95% confidence level and 4 degree of freedom (t 
= 2.77) 
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7. Determination of haloperidol in tablets 
The assay of haloperidol was carried out on marketed pharmaceutical 
formulations by the proposed method and a reference method [17]. The results 
are summarized in Table 2.4. The results were compared with those obtained 
by the reference method with regard to accuracy (t-test) and precision (F-test) 
at 95% confidence level. As can be seen from the table that the calculated t-
and F-values did not exceed the tabulated values at 95% confidence level 
which indicated similar levels of accuracy and precision. Interval hypothesis 
was also tested and the true bias based on the recovery experiments were 
calculated using the equation [30]: 
e\xl -SpV/m) - 20xiX2 + e^ (x | -Sp¥/n2) = o 
The lower limit (Oi) and upper limit (du) of the confidence interval are 
obtained: 
Where 
eu = '-
61 = 
a = {xl -Sp^t^/m) 
b = 20XiX2 
c = (x | -Sp^t^/n2) 
-b + V62 -Aac 
la 
-b - y/b^ - Aac 
la 
Where, x\ and x\ are the mean value obtained by the proposed and reference 
methods, respectively.ni and n2are the number of respective measurements. Sp 
is the pooled standard deviation and t-is the one sided t-value at 95% 
confidence level. The values of Qi and Q^ for the assay of serenace and 
hexidol tablets are reported in Table 2.4. In pharmaceutical analysis, a bias of 
< ± 2 is acceptable [31]. As can be seen from the table that the bias calculated 
for the assay of serenace and hexidol is less than ±2% which indicated that the 
accuracy and precision are within acceptable limits. The interval hypothesis 
test has also confirmed that there is no significant difference in the 
performance of the proposed and reference methods at 95% confidence level. 
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8. Conclusion 
The proposed method has the advantages of simpUcity and reliabiUty for 
determination of haloperidol in pure and commercial tablets. The effects of 
various parameters have been studied to optimize the reaction conditions .The 
reagents utilized in the proposed method are cheaper and easily available. 
Under the optimized conditions. Beer's law was obeyed in the concentration 
range of 3.6-10.8|ag/mL haloperidol with the molar absorptivity of 2.84x10"* 
litre mof' cm'' which indicated high sensitivity of the method. The results 
obtained by the proposed method were compared with those obtained by the 
reference method. The data obtained by both the methods were found to be 
very close to each other and also close to those given by the pharmaceutical 
companies. These advantages encourage the application of the proposed 
method in routine quality control analysis of haloperidol in commercial 
tablets. 
151 
REFERENCES 
[I] J.P. Remington, Remington's pharmaceutical sciences, 18'" Edn.. 
Easton: Mack Pub, 1990. 
[2] V.M. Sahu, M.S.Thesis, Mechanism of action of antipsychotics, 
haloperidol and olanzapine in vitro, Virginia Polytechnic Institute and 
State University, Blacksburg, Virginia, USA, 2001. 
[3] D.R. Sibley and F.J. Monsma, Jr,MolecuIar biology of dopamine 
receptors,Trends Pharmacol.Sci.,13 (1992) 61-69. 
[4] G. Bernard and A. Simona, The haloperidol story, Ann. Clin. 
Psychiatry, 17(2005)137-140. 
[5] A.C.Serrano, Haloperidol-its use in children, J. Clin. Psychiatry,42 
(1981)154-156. 
[6] T.M. Gore, U. Garg and G.L. Keams, Haloperidol decanoate overdose 
in an adolescent, Paediatric and Perinatal Drug Therapy,7 (2006) 19-
22. 
[7] A. Forsman and R.Ohman, Studies on serum protein binding of 
haloperidol, Curr. Ther. Res. Clin. Exp., 21 (1977) 245-255. 
[8] J.S Froemming, Y.W. Lam, M.W. Jann and CM. Davis, 
Pharmacokinetics of haloperidol, Clin. Pharmacokinet.,17 (1989) 396-
423. 
[9] A.Pangaggio and D.S. Greene, High pressure liquid chromatographic 
determination of haloperidol stability, Drug Dev.Ind. Pharm., 9 (1983) 
485-492. 
[10] C.A. Janicki and C.Y. Ko, Analytical profiles of drug substances. 
Academic Press, New York, 1980. 
[II] S.Ouanes, M.Kallel, H.Trabelsi, F.safta and K.Bouzouita ,Zero-
crossing derivative spectrophotometry for the determination of 
haloperidol in presence of parabens, J.Pharm.Biomed.Anal., 17(1998) 
361-364. 
[12] R.K.Sangeeta,T.Sudhakaran, T.K.Ravi and M.M.Raja, IR 
interpretation, derivative UV spectra and validated UV spectroscopy 
method for the estimation of haloperidol in tablet dosage forms, 
Int.J.Pharm.Res.Anal., 3(2013) 18-21. 
152 
[13] M.Stolarczyk,A.Apola, J.Krzek and A.Sajdak, Validation of derivative 
spectrophotometry method for determination of active ingredients from 
neuroleptics in pharmaceutical preparation, Acta Pol.Pharm.-Drug 
Res., 66(2009)351-356. 
[14] S.P. Wate and A.A.Borkar, Simultaneous spectrophotometric 
estimation of haloperidol and trihexaphenidyl in tablet, Indian 
J.Pharm.Sci., 72 (2010) 265-267. 
[15] A.A.Attama,P.O.Nnamani, M.U.Adikwu, and F.O. Akidi, 
Spectrophotometric determination of haloperidol by charge transfer 
interaction with chloranilic acid, S.T.P. Pharm.Sci.,13 (2003) 419-421. 
[16] H.F.Askal, Spectrophotometric study of charge transfer complexes of 
some pharmaceutical butyrophenones, Talanta, 44 (1997) 1749-1755. 
[17] N.Rahman, A.Khatoon and H.Rahman, Studies on the development of 
spectrophotometric method for the determination of haloperidol in 
pharmaceutical preparations,Quim.Nova, 35 (2012) 392-397. 
[18] N.Rahman and S.Siddiqui, Development and validation of 
spectrofluorimetric method for the determination of haloperidol in 
pharmaceutical dosage forms, DrugTest.Anal., 2 (2010) 252-258. 
[19] H.Ebrahimzadeh, Z.Dehghani, A.A.Asgharinezhad, N.Shekari and 
K.Molaei, Determination of haloperidol in biological samples with the 
aid of ultra sound -assisted emulsification microextraction followed 
by HPLC-DAD, J.Sep.Sci., 36 (2013) 1597-1603. 
[20] M.Pujadas, S.Pichini, E.Civit, E. Santamarina, K.Prez, and R.Dela 
Torre, A simple and reliable procedure for the determination of 
psychoactive drugs in oral fluid by gas chromatography-mass 
spectrometry, J.Pharm. Biomed. Anal., 44 (2007) 594-601. 
[21] A.Maslanka,and J.Krzek, Densitometric high performance thin layer 
chromatography identification and quantitative analysis of 
psychotropic drugs, J.Assoc. Off Anal. Chem. Int., 88 (2005) 70-79. 
[22] S.Mennickent, L.Pino, M.Vega, C.G.Godoy, and M.de Diego, 
Quanthative determination of haloperidol in tablets by high 
performance thin-layer chromatography,J.Sep. Sci., 30 (2007) 772-
777. 
53 
[23] International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use, ICH 
Harmonisation Tripartite Guidelines, Validation of Analytical 
Procedures: Text and Methodology, ICH,Q2(R1), 2005. 
[24] D.A.Skoog, D.M.West, F.J.HoUer and S.R.Crouch, Fundamentals of 
analytical chemistry, S"^  edn., Thomson Asia Pte Ltd., Singapore. 
2004,P.805. 
[25] A.Attama, P.O.Nnamani, M.U.Adikwu, and F.O Akidi. 
Thermodynamic consideration of the charge transfer interaction of the 
donor: acceptor type between chloranilic acid and 
haloperidol,Chem.Pharm.Bull.,52 (2004) 303-306. 
[26] M. Shamsipur, L. Shafiee-Dastgerdi, Z. Telebpour, and S.J 
Haghgoo,''^F NMR as a powerful technique for the assay of anti-
psychotic drug haloperidol in human serum and pharmaceutical 
formulation, J.Pharm.Biomed.Anal.,23 (2007) 1116-1121. 
[27] H.Y.Aboul-Enein, I.Ali and H.Hoenen, Rapid determination of 
haloperidol and its metabolites in human plasma by HPLC using 
monolithic silica column and solid-phase extraction, J.Biomed. 
Chromatogr., 20 (2006) 760-764. 
[28] A. Forsman, E. Martensson, G. Nyberg and R. Ohman, A gas 
chromatographic method for determining haloperidol, Naunyn-
Schmiedeberg' Archives of Pharmacology, 286 (1974) 113-124. 
[29] S.M.Wu,W.K. Ko, H.L.Wu and S.H.Chen, Trace analysis of 
haloperidol and its chiral metabolite in plasma by capillary 
electrophoresis, J. Chromatogr A. 846 (1999) 239-243. 
[30] C.Hartmann, J.S. Verbeke, W.P Enninckx, Y.V.Heyden, P.Vankeerber, 
D. L. Massrat, Reappraisal of Hypothesis Testing for Method 
Validation: Detection of Systematic Error by Comparing the Means of 
Two Methods or of Two Laboratories Anal.Chem.,(1995) 4491. 
[31] Acceptable methods in drugs directorate guidelines, Canada Health 
protection branch, ministry of national health and welfare, draft, 
Ottawa, Canada,(1992). 
^_5^.». -A- . -U,T.~; . . 
;' '" 4 .-•.t^ :i- '• 
" • • * < " • . ; . • . , 
